P A Ringen1, R Nesvåg2, S Helle3, T V Lagerberg1, E H Lange4, E M Løberg3, I Agartz5, O A Andreassen1, I Melle1. 1. Division of Mental Health and Addiction,Oslo University Hospital,Oslo,Norway. 2. Department of mental disorders,Norwegian Institute of Public Health,Oslo,Norway. 3. Division of Psychiatry,Haukeland University Hospital,Bergen,Norway. 4. NORMENT, K. G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo,Oslo,Norway. 5. Department of Psychiatric Research,Diakonhjemmet Hospital,Oslo,Norway.
Abstract
BACKGROUND: Cannabis use disorder is associated with an earlier age at onset and a more severe outcome of schizophrenia spectrum disorders. The role of cannabis use before the onset of illness (premorbid cannabis use) has not been fully investigated. We here examined how amount and type of premorbid cannabis use was associated with the later course of illness including current substance use, symptoms and level of functioning in schizophrenia spectrum disorder. METHOD: We used a naturalistic sample of patients with DSM-IV schizophrenia spectrum disorders with a comprehensive history of illness and substance use. Data on premorbid substance use was obtained from comprehensive self-report. The relationship to outcome was investigated using regression models that included current substance use and premorbid functioning. RESULTS: Pre-schizophrenia cannabis use was significantly associated with more severe psychotic symptoms and impaired functioning. Higher levels of premorbid cannabis use were associated with higher levels of current psychotic symptoms. These associations were independent of current substance use and premorbid functioning. Early use of cannabis (age <17 years) was associated with earlier age at onset of psychosis, independently of potential confounders. CONCLUSIONS: Pre-psychosis cannabis use affects illness outcome in schizophrenia spectrum disorders, and is associated with lower age at onset of psychosis. These findings of independent negative effects of premorbid cannabis use in schizophrenia suggest that a limitation of the general use of cannabis may have beneficial health effects.
BACKGROUND: Cannabis use disorder is associated with an earlier age at onset and a more severe outcome of schizophrenia spectrum disorders. The role of cannabis use before the onset of illness (premorbid cannabis use) has not been fully investigated. We here examined how amount and type of premorbid cannabis use was associated with the later course of illness including current substance use, symptoms and level of functioning in schizophrenia spectrum disorder. METHOD: We used a naturalistic sample of patients with DSM-IV schizophrenia spectrum disorders with a comprehensive history of illness and substance use. Data on premorbid substance use was obtained from comprehensive self-report. The relationship to outcome was investigated using regression models that included current substance use and premorbid functioning. RESULTS: Pre-schizophrenia cannabis use was significantly associated with more severe psychotic symptoms and impaired functioning. Higher levels of premorbid cannabis use were associated with higher levels of current psychotic symptoms. These associations were independent of current substance use and premorbid functioning. Early use of cannabis (age <17 years) was associated with earlier age at onset of psychosis, independently of potential confounders. CONCLUSIONS: Pre-psychosis cannabis use affects illness outcome in schizophrenia spectrum disorders, and is associated with lower age at onset of psychosis. These findings of independent negative effects of premorbid cannabis use in schizophrenia suggest that a limitation of the general use of cannabis may have beneficial health effects.
Entities:
Keywords:
Age at onset; cannabis; premorbid; psychosis; schizophrenia
Authors: Roman Kotov; Katherine G Jonas; William T Carpenter; Michael N Dretsch; Nicholas R Eaton; Miriam K Forbes; Kelsie T Forbush; Kelsey Hobbs; Ulrich Reininghaus; Tim Slade; Susan C South; Matthew Sunderland; Monika A Waszczuk; Thomas A Widiger; Aidan G C Wright; David H Zald; Robert F Krueger; David Watson Journal: World Psychiatry Date: 2020-06 Impact factor: 49.548
Authors: Valerio Ricci; Giovanni Martinotti; Franca Ceci; Stefania Chiappini; Francesco Di Carlo; Julius Burkauskas; Ottavia Susini; Debora Luciani; Diego Quattrone; Domenico De Berardis; Mauro Pettorruso; Giuseppe Maina; Massimo Di Giannantonio Journal: Int J Environ Res Public Health Date: 2021-11-30 Impact factor: 3.390
Authors: Laura Ferraro; Caterina La Cascia; Daniele La Barbera; Teresa Sanchez-Gutierrez; Giada Tripoli; Fabio Seminerio; Crocettarachele Sartorio; Giovanna Marrazzo; Lucia Sideli; Celso Arango; Manuel Arrojo; Miguel Bernardo; Julio Bobes; Cristina Marta Del-Ben; Charlotte Gayer-Anderson; Hannah E Jongsma; James B Kirkbride; Antonio Lasalvia; Sarah Tosato; Pierre-Michel Llorca; Paulo Rossi Menezes; Bart P Rutten; Jose Luis Santos; Julio Sanjuán; Jean-Paul Selten; Andrei Szöke; Ilaria Tarricone; Roberto Muratori; Andrea Tortelli; Eva Velthorst; Victoria Rodriguez; Andrea Quattrone; Peter B Jones; Jim Van Os; Evangelos Vassos; Craig Morgan; Lieuwe de Haan; Ulrich Reininghaus; Alastair G Cardno; Marta Di Forti; Robin M Murray; Diego Quattrone Journal: Schizophr Res Date: 2021-08-14 Impact factor: 4.939
Authors: Diego Quattrone; Laura Ferraro; Giada Tripoli; Caterina La Cascia; Harriet Quigley; Andrea Quattrone; Hannah E Jongsma; Simona Del Peschio; Giusy Gatto; Charlotte Gayer-Anderson; Peter B Jones; James B Kirkbride; Daniele La Barbera; Ilaria Tarricone; Domenico Berardi; Sarah Tosato; Antonio Lasalvia; Andrei Szöke; Celso Arango; Miquel Bernardo; Julio Bobes; Cristina Marta Del Ben; Paulo Rossi Menezes; Pierre-Michel Llorca; Jose Luis Santos; Julio Sanjuán; Andrea Tortelli; Eva Velthorst; Lieuwe de Haan; Bart P F Rutten; Michael T Lynskey; Tom P Freeman; Pak C Sham; Alastair G Cardno; Evangelos Vassos; Jim van Os; Craig Morgan; Ulrich Reininghaus; Cathryn M Lewis; Robin M Murray; Marta Di Forti Journal: Psychol Med Date: 2020-03-18 Impact factor: 7.723